Welcome to our dedicated page for Terns Pharmaceuticals SEC filings (Ticker: TERN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Terns Pharmaceuticals, Inc. (TERN) SEC filings page provides access to the company’s official U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other registered offerings. As a Nasdaq Global Select Market issuer, Terns uses these filings to report material events such as clinical data updates, financial results and capital markets transactions related to its oncology-focused business.
For investors tracking TERN-701, Terns’ lead program and a highly selective, oral, allosteric BCR-ABL (BCR::ABL1) inhibitor for chronic myeloid leukemia (CML), Form 8-K filings often incorporate or reference press releases that summarize key clinical findings from the CARDINAL trial (NCT06163430). These filings detail major molecular response (MMR) and deep molecular response (DMR) rates, safety and tolerability observations, and characteristics of heavily pretreated CML patient populations, as well as milestones like selection for oral presentations at the American Society of Hematology (ASH) Annual Meeting.
Terns’ SEC filings also document financial results and capital raises, including underwritten public offerings of common stock registered on Form S-3. Related prospectus supplements describe intended uses of proceeds, such as funding research, clinical trials, development and manufacturing of key product candidates, including TERN-701, and supporting general corporate purposes.
Through this page, users can review how Terns communicates material information to the market, from quarterly financial updates furnished on Form 8-K to other event-driven disclosures. AI-powered tools on the platform can help summarize lengthy filings, highlight sections related to TERN-701 clinical data, CARDINAL trial progress, legacy metabolic programs like TERN-501, TERN-801 and TERN-601, and clarify the implications of financing and regulatory updates for the company’s oncology-focused strategy.